Alkermes plc. (ALKS)
Alkermes plc. (ALKS) from its SEC filings: 2025 revenue $1.5 billion (-5% vs the year before), net margin 16%, free cash flow $480.3 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $1.5 billion |
| Revenue growth | -5% |
| Net income | $241.7 million |
| Net margin | 16.4% |
| Free cash flow | $480.3 million |
| Diluted EPS | $1.43 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +27% |
| Cash | $511.5 million |
| Long-term debt | $1.5 billion |
| Share count, 1 year | +2% |
| Fundamentals check | Strong fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-24. Education only, not financial advice.